Business
Tenaya Therapeutics Provides 2022 Business Updates
Company announces development candidate selection of its second gene therapy program, TN-401, targeting the leading genetic cause of arrhythmogenic right
About this update from Tenaya Therapeutics, Inc.
[{"type":"text","content":"\n\nCompany announces development candidate selection of its second gene therapy program, TN-401, targeting the leading genetic cause of arrhythmogenic right ventricular cardiomyopathy (gARVC)\n\n\n\nIND applications for TN-201 and TN-301 (previously named TYA-11631) expected to be submitted in the second half of 2022\n\n\n\nAppoints Jennifer Drimmer, J.D., as General Counsel\n\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nTenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today provided a 2022 business update including the selection of TN-401 as the development candidate for the treatment of Genetic Arrhythmogenic Right Ventricular Cardiomyopathy (gARVC) due to PKP2 gene mutation. In addition, Tenaya appointed Jennifer Drimmer, J.D., as its General Counsel.\n\n“After an exciting year in 2021, Tenaya is off to a strong start in 2022 with the selection of TN-401 as a development candidate that provides new hope to patients and families fighting gARVC,” said Faraz Ali, Chief Executive Officer of Tenaya. “With three therapeutic candidates now advancing toward the clinic, we look forward to another year of important milestones and operational and scientific progress. We also continue to strengthen the leadership team with the appointment of Jennifer who adds highly relevant experience, depth, and diversity. We have never been better positioned to deliver on our mission to fundamentally change the paradigm of treatment for both rare and prevalent forms of heart disease.”\n\nBusiness and Program Updates\n\n\nTN-401 - PKP2 Gene Therapy Program for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy (gARVC):\n\n\nTenaya has nominated TN-401 as a clinical drug candidate to treat patients carrying PKP2 gene mutations. Mutations of the PKP2 gene are the leading genetic cause of ARVC and can cause severe disease including significant arrhythmia and sudden cardiac death in adults and children. These mutations are estimated to affect more than 70,000 patients in the US alone. Based on publicly available information to date, we believe there are no approved disease-specific therapies.\n\n\nTenaya expects to present new preclinical data supporting the TN-401 program including dose-dependent efficacy, su...